Polyrizon Ltd. Ordinary Shares (PLRZ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Polyrizon Ltd. Ordinary Shares (PLRZ) has a cash flow conversion efficiency ratio of -0.099x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.82 Million) by net assets ($18.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Polyrizon Ltd. Ordinary Shares stock valuation for the company's overall valuation and market capitalisation.
Polyrizon Ltd. Ordinary Shares - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Polyrizon Ltd. Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Polyrizon Ltd. Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Polyrizon Ltd. Ordinary Shares ranked by their cash flow conversion efficiency. See debt repayment capacity of Polyrizon Ltd. Ordinary Shares to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Alice QUEEN Ltd
AU:AQX
|
5.144x |
|
Atomo Diagnostics Ltd
AU:AT1
|
-0.145x |
|
Zenith Exports Limited
NSE:ZENITHEXPO
|
0.028x |
|
Andira Agro Tbk PT
JK:ANDI
|
-0.114x |
|
XINYUAN REAL ESTATE ADR20
F:3XR
|
N/A |
|
Ecomiam SA
PA:ALECO
|
-0.357x |
|
Spring Art Holdings Bhd
KLSE:0216
|
0.013x |
|
NTG Clarity Networks Inc.
V:NCI
|
-0.125x |
Annual Cash Flow Conversion Efficiency for Polyrizon Ltd. Ordinary Shares (2020–2024)
The table below shows the annual cash flow conversion efficiency of Polyrizon Ltd. Ordinary Shares from 2020 to 2024. View Polyrizon Ltd. Ordinary Shares share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.29 Million | $-1.15 Million | -0.217x | -107.72% |
| 2023-12-31 | $-191.00K | $-537.00K | 2.812x | +61.94% |
| 2022-12-31 | $-652.00K | $-1.13 Million | 1.736x | -98.94% |
| 2021-12-31 | $-3.00K | $-492.00K | 164.000x | +3694.52% |
| 2020-12-31 | $16.00K | $-73.00K | -4.563x | -- |
About Polyrizon Ltd. Ordinary Shares
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nas… Read more